Next Article in Journal
Acute Exposure to Zearalenone Disturbs Intestinal Homeostasis by Modulating the Wnt/β-Catenin Signaling Pathway
Previous Article in Journal
Polymethoxy-1-Alkenes Screening of Chlorella and Spirulina Food Supplements Coupled with In Vivo Toxicity Studies
Previous Article in Special Issue
Botulinum Toxin Therapy Combined with Rehabilitation for Stroke: A Systematic Review of Effect on Motor Function
Open AccessReview

Use of Botulinum Toxin in Orofacial Clinical Practice

Oral Surgery Department, Dental School, University of Sevilla, 41009 Sevilla, Spain
*
Authors to whom correspondence should be addressed.
Toxins 2020, 12(2), 112; https://doi.org/10.3390/toxins12020112
Received: 13 December 2019 / Revised: 22 January 2020 / Accepted: 5 February 2020 / Published: 11 February 2020
Introduction: Botulinum neurotoxin (BoNT) is a potent biological toxin and powerful therapeutic tool for a growing number of clinical orofacial applications. BoNT relaxes striated muscle by inhibiting acetylcholine’s release from presynaptic nerve terminals, blocking the neuromuscular junction. It also has an antinociceptive effect on sensory nerve endings, where BoNT and acetylcholine are transported axonally to the central nervous system. In dentistry, controlled clinical trials have demonstrated BoNT’s efficiency in pathologies such as bruxism, facial paralysis, temporomandibular joint (TMJ) disorders, neuropathic pain, sialorrhea, dystonia and more. Aim: This study’s aim was to conduct a systematic literature review to assess the most recent high-level clinical evidence for BoNT’s efficacy and for various protocols (the toxin used, dilution, dosage and infiltration sites) used in several orofacial pathologies. Materials and methods: We systematically searched the MedLine database for research papers published from 2014 to 2019 with randomly allocated studies on humans. The search included the following pathologies: bruxism, dislocation of the TMJ, orofacial dystonia, myofascial pain, salivary gland disease, orofacial spasm, facial paralysis, sialorrhea, Frey syndrome and trigeminal neuralgia. Results: We found 228 articles, of which only 20 met the inclusion criteria: bruxism (four articles), orofacial dystonia (two articles), myofascial pain (one article), salivary gland disease (one article), orofacial spasm (two articles), facial paralysis (three articles), sialorrhea (four articles) or trigeminal neuralgia (three articles). Discussion: The clinical trials assessed showed variations in the dosage, application sites and musculature treated. Thus, applying BoNT can reduce symptoms related to motor muscular activity in the studied pathologies efficiently enough to satisfy patients. We did not identify the onset of any important side effects in the literature reviewed. We conclude that treatment with BoNT seems a safe and effective treatment for the reviewed pathologies.
Keywords: botulinum toxin; bruxism; salivary fistula; facial spasm; sialorrhea; orofacial dystonia; myofascial pain; facial paralysis; Frey syndrome; lockjaw; trigeminal neuralgia botulinum toxin; bruxism; salivary fistula; facial spasm; sialorrhea; orofacial dystonia; myofascial pain; facial paralysis; Frey syndrome; lockjaw; trigeminal neuralgia
MDPI and ACS Style

Serrera-Figallo, M.-A.; Ruiz-de-León-Hernández, G.; Torres-Lagares, D.; Castro-Araya, A.; Torres-Ferrerosa, O.; Hernández-Pacheco, E.; Gutierrez-Perez, J.-L. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins 2020, 12, 112.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop